These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23237838)

  • 1. Synthesis and biological activity of aminophthalazines and aminopyridazines as novel inhibitors of PGE2 production in cells.
    Medda F; Sells E; Chang HH; Dietrich J; Chappeta S; Smith B; Gokhale V; Meuillet EJ; Hulme C
    Bioorg Med Chem Lett; 2013 Jan; 23(2):528-31. PubMed ID: 23237838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.
    Smith B; Chang HH; Medda F; Gokhale V; Dietrich J; Davis A; Meuillet EJ; Hulme C
    Bioorg Med Chem Lett; 2012 May; 22(10):3567-70. PubMed ID: 22516282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and cytotoxic evaluation of some new phthalazinylpiperazine derivatives.
    Liu Y; Zhang S; Li Y; Wang J; Song Y; Gong P
    Arch Pharm (Weinheim); 2012 Apr; 345(4):287-93. PubMed ID: 22006840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and anticancer activities of novel 1,4-disubstituted phthalazines.
    Li J; Zhao YF; Yuan XY; Xu JX; Gong P
    Molecules; 2006 Jul; 11(7):574-82. PubMed ID: 17971729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
    Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and anticancer activities of novel 1,2,4-triazolo[3,4-a]phthalazine derivatives.
    Xue DQ; Zhang XY; Wang CJ; Ma LY; Zhu N; He P; Shao KP; Chen PJ; Gu YF; Zhang XS; Wang CF; Ji CH; Zhang QR; Liu HM
    Eur J Med Chem; 2014 Oct; 85():235-44. PubMed ID: 25086915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives.
    Zhang S; Zhao Y; Liu Y; Chen D; Lan W; Zhao Q; Dong C; Xia L; Gong P
    Eur J Med Chem; 2010 Aug; 45(8):3504-10. PubMed ID: 20537434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones.
    Eldehna WM; Ibrahim HS; Abdel-Aziz HA; Farrag NN; Youssef MM
    Eur J Med Chem; 2015 Jan; 89():549-60. PubMed ID: 25462265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 4-arylphthalazones bearing benzenesulfonamide as anti-inflammatory and anti-cancer agents.
    Yaseen S; Ovais S; Bashir R; Rathore P; Samim M; Singh S; Nair V; Javed K
    Arch Pharm (Weinheim); 2013 Jun; 346(6):491-8. PubMed ID: 23670888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
    El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in-vitro antitumor activity of 1-[3-(indol-1-yl)prop-1-yn-1-yl]phthalazines and related compounds.
    Haider N; Kabicher T; Käferböck J; Plenk A
    Molecules; 2007 Aug; 12(8):1900-9. PubMed ID: 17960095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.
    Prime ME; Courtney SM; Brookfield FA; Marston RW; Walker V; Warne J; Boyd AE; Kairies NA; von der Saal W; Limberg A; Georges G; Engh RA; Goller B; Rueger P; Rueth M
    J Med Chem; 2011 Jan; 54(1):312-9. PubMed ID: 21128645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
    Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
    Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors.
    Lu X; Peng Y; Wang C; Yang J; Bao X; Dong Q; Zhao W; Tan W; Dong X
    Eur J Med Chem; 2017 Sep; 138():384-395. PubMed ID: 28688278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: Apoptosis-inductive and PCAF-inhibitory effects.
    Turky A; Bayoumi AH; Ghiaty A; El-Azab AS; A-M Abdel-Aziz A; Abulkhair HS
    Bioorg Chem; 2020 Aug; 101():104019. PubMed ID: 32615465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and PGE₂ production inhibition of s-triazine derivatives as a novel scaffold in RAW 264.7 macrophage cells.
    Kang SM; Lee J; Jin JH; Kim M; Lee S; Lee HH; Shin JS; Lee KT; Lee JY
    Bioorg Med Chem Lett; 2014 Dec; 24(23):5418-22. PubMed ID: 25453800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors.
    El-Helby AA; Ayyad RRA; Sakr H; El-Adl K; Ali MM; Khedr F
    Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition.
    Elmeligie S; Aboul-Magd AM; Lasheen DS; Ibrahim TM; Abdelghany TM; Khojah SM; Abouzid KAM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1347-1367. PubMed ID: 31322015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.
    Huang Z; Zhao B; Qin Z; Li Y; Wang T; Zhou W; Zheng J; Yang S; Shi Y; Fan Y; Xiang R
    Eur J Med Chem; 2019 Nov; 181():111541. PubMed ID: 31382120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.